Which has stronger valuation & earnings, ALMS or MGNX?

MacroGenics has higher revenue and earnings than Alumis. MacroGenics is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alumis $24.05M 37.30 -$243.32M -$3.86 N/A MacroGenics $175.14M 1.32 -$74.62M -$0.22 N/A

Is ALMS or MGNX more profitable?

MacroGenics has a net margin of -8.70% compared to Alumis' net margin of -5,933.46%. Alumis' return on equity of -93.15% beat MacroGenics' return on equity. Company Net Margins Return on Equity Return on Assets Alumis -5,933.46% -93.15% -74.50% MacroGenics -8.70% -109.26% -18.70%

Does the media prefer ALMS or MGNX?

In the previous week, Alumis and Alumis both had 1 articles in the media. Alumis' average media sentiment score of 1.11 beat MacroGenics' score of 0.00 indicating that Alumis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alumis 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MacroGenics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor MGNX or ABUS?

In the previous week, Arbutus Biopharma had 7 more articles in the media than MacroGenics. MarketBeat recorded 8 mentions for Arbutus Biopharma and 1 mentions for MacroGenics. Arbutus Biopharma's average media sentiment score of 0.68 beat MacroGenics' score of 0.00 indicating that Arbutus Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MacroGenics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arbutus Biopharma 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MGNX or RIGL?

In the previous week, Rigel Pharmaceuticals had 2 more articles in the media than MacroGenics. MarketBeat recorded 3 mentions for Rigel Pharmaceuticals and 1 mentions for MacroGenics. MacroGenics' average media sentiment score of 0.00 equaled Rigel Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MacroGenics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rigel Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor MGNX or JBIO?

In the previous week, Jade Biosciences had 10 more articles in the media than MacroGenics. MarketBeat recorded 11 mentions for Jade Biosciences and 1 mentions for MacroGenics. Jade Biosciences' average media sentiment score of 0.17 beat MacroGenics' score of 0.00 indicating that Jade Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MacroGenics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Jade Biosciences 0 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

MacroGenics (MGNX) Competitors

$3.54 -0.10 (-2.61%)

As of 01:31 PM Eastern

Compare

MGNX vs. ALMS, ABUS, RIGL, JBIO, and SANA

Should you buy MacroGenics stock or one of its competitors? MacroGenics's main competitors and comparable companies include Alumis (ALMS), Arbutus Biopharma (ABUS), Rigel Pharmaceuticals (RIGL), Jade Biosciences (JBIO), and Sana Biotechnology (SANA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does MacroGenics compare to Alumis?

Alumis (NASDAQ:ALMS) and MacroGenics (NASDAQ:MGNX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Alumis currently has a consensus price target of $33.27, indicating a potential upside of 380.13%. MacroGenics has a consensus price target of $6.33, indicating a potential upside of 73.99%. Given Alumis' stronger consensus rating and higher possible upside, equities research analysts plainly believe Alumis is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alumis	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

Alumis has a beta of -0.38, indicating that its stock price is 138% less volatile than the broader market. Comparatively, MacroGenics has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market.

In the previous week, Alumis and Alumis both had 1 articles in the media. Alumis' average media sentiment score of 1.11 beat MacroGenics' score of 0.00 indicating that Alumis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alumis	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MacroGenics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MacroGenics has higher revenue and earnings than Alumis. MacroGenics is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alumis	$24.05M	37.30	-$243.32M	-$3.86	N/A
MacroGenics	$175.14M	1.32	-$74.62M	-$0.22	N/A

96.9% of MacroGenics shares are held by institutional investors. 33.7% of Alumis shares are held by company insiders. Comparatively, 13.6% of MacroGenics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

MacroGenics has a net margin of -8.70% compared to Alumis' net margin of -5,933.46%. Alumis' return on equity of -93.15% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alumis	-5,933.46%	-93.15%	-74.50%
MacroGenics	-8.70%	-109.26%	-18.70%

Summary

Alumis beats MacroGenics on 9 of the 16 factors compared between the two stocks.

How does MacroGenics compare to Arbutus Biopharma?

MacroGenics (NASDAQ:MGNX) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

Arbutus Biopharma has lower revenue, but higher earnings than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MacroGenics	$175.14M	1.32	-$74.62M	-$0.22	N/A
Arbutus Biopharma	$14.08M	63.04	-$33.50M	$0.79	5.67

Arbutus Biopharma has a net margin of 84.22% compared to MacroGenics' net margin of -8.70%. Arbutus Biopharma's return on equity of 90.98% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MacroGenics	-8.70%	-109.26%	-18.70%
Arbutus Biopharma	84.22%	90.98%	82.34%

MacroGenics presently has a consensus price target of $6.33, indicating a potential upside of 73.99%. Arbutus Biopharma has a consensus price target of $5.00, indicating a potential upside of 11.61%. Given MacroGenics' higher probable upside, analysts clearly believe MacroGenics is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
Arbutus Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

96.9% of MacroGenics shares are owned by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are owned by institutional investors. 13.6% of MacroGenics shares are owned by company insiders. Comparatively, 19.9% of Arbutus Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

MacroGenics has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market. Comparatively, Arbutus Biopharma has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market.

In the previous week, Arbutus Biopharma had 7 more articles in the media than MacroGenics. MarketBeat recorded 8 mentions for Arbutus Biopharma and 1 mentions for MacroGenics. Arbutus Biopharma's average media sentiment score of 0.68 beat MacroGenics' score of 0.00 indicating that Arbutus Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MacroGenics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arbutus Biopharma	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Arbutus Biopharma beats MacroGenics on 11 of the 16 factors compared between the two stocks.

How does MacroGenics compare to Rigel Pharmaceuticals?

MacroGenics (NASDAQ:MGNX) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

MacroGenics has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market.

Rigel Pharmaceuticals has a net margin of 116.30% compared to MacroGenics' net margin of -8.70%. Rigel Pharmaceuticals' return on equity of 22.95% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MacroGenics	-8.70%	-109.26%	-18.70%
Rigel Pharmaceuticals	116.30%	22.95%	17.19%

MacroGenics currently has a consensus target price of $6.33, suggesting a potential upside of 73.99%. Rigel Pharmaceuticals has a consensus target price of $59.00, suggesting a potential upside of 27.95%. Given MacroGenics' higher probable upside, equities research analysts plainly believe MacroGenics is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
Rigel Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Rigel Pharmaceuticals has higher revenue and earnings than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MacroGenics	$175.14M	1.32	-$74.62M	-$0.22	N/A
Rigel Pharmaceuticals	$294.28M	2.90	$367.02M	$16.32	2.83

96.9% of MacroGenics shares are owned by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 13.6% of MacroGenics shares are owned by company insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Rigel Pharmaceuticals had 2 more articles in the media than MacroGenics. MarketBeat recorded 3 mentions for Rigel Pharmaceuticals and 1 mentions for MacroGenics. MacroGenics' average media sentiment score of 0.00 equaled Rigel Pharmaceuticals'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MacroGenics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rigel Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Rigel Pharmaceuticals beats MacroGenics on 11 of the 15 factors compared between the two stocks.

How does MacroGenics compare to Jade Biosciences?

MacroGenics (NASDAQ:MGNX) and Jade Biosciences (NASDAQ:JBIO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

In the previous week, Jade Biosciences had 10 more articles in the media than MacroGenics. MarketBeat recorded 11 mentions for Jade Biosciences and 1 mentions for MacroGenics. Jade Biosciences' average media sentiment score of 0.17 beat MacroGenics' score of 0.00 indicating that Jade Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MacroGenics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Jade Biosciences	0 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MacroGenics has higher revenue and earnings than Jade Biosciences. MacroGenics is trading at a lower price-to-earnings ratio than Jade Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MacroGenics	$175.14M	1.32	-$74.62M	-$0.22	N/A
Jade Biosciences	N/A	N/A	-$127.41M	-$1.92	N/A

96.9% of MacroGenics shares are held by institutional investors. 13.6% of MacroGenics shares are held by company insiders. Comparatively, 23.1% of Jade Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

MacroGenics currently has a consensus target price of $6.33, indicating a potential upside of 73.99%. Jade Biosciences has a consensus target price of $51.75, indicating a potential upside of 285.91%. Given Jade Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Jade Biosciences is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

Jade Biosciences has a net margin of 0.00% compared to MacroGenics' net margin of -8.70%. Jade Biosciences' return on equity of -49.11% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MacroGenics	-8.70%	-109.26%	-18.70%
Jade Biosciences	N/A	-49.11%	-45.62%

MacroGenics has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market. Comparatively, Jade Biosciences has a beta of 1.64, meaning that its share price is 64% more volatile than the broader market.

Summary

Jade Biosciences beats MacroGenics on 11 of the 16 factors compared between the two stocks.

How does MacroGenics compare to Sana Biotechnology?

Sana Biotechnology (NASDAQ:SANA) and MacroGenics (NASDAQ:MGNX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Sana Biotechnology has a net margin of 0.00% compared to MacroGenics' net margin of -8.70%. Sana Biotechnology's return on equity of -103.02% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-103.02%	-39.16%
MacroGenics	-8.70%	-109.26%	-18.70%

Sana Biotechnology presently has a consensus target price of $9.33, suggesting a potential upside of 239.39%. MacroGenics has a consensus target price of $6.33, suggesting a potential upside of 73.99%. Given Sana Biotechnology's stronger consensus rating and higher probable upside, equities research analysts clearly believe Sana Biotechnology is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

88.2% of Sana Biotechnology shares are owned by institutional investors. Comparatively, 96.9% of MacroGenics shares are owned by institutional investors. 25.4% of Sana Biotechnology shares are owned by insiders. Comparatively, 13.6% of MacroGenics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Sana Biotechnology has a beta of 2.18, suggesting that its share price is 118% more volatile than the broader market. Comparatively, MacroGenics has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market.

In the previous week, MacroGenics had 1 more articles in the media than Sana Biotechnology. MarketBeat recorded 1 mentions for MacroGenics and 0 mentions for Sana Biotechnology. Sana Biotechnology's average media sentiment score of 0.00 equaled MacroGenics'average media sentiment score.

Company	Overall Sentiment
Sana Biotechnology	Neutral
MacroGenics	Neutral

MacroGenics has higher revenue and earnings than Sana Biotechnology. MacroGenics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.76	N/A
MacroGenics	$175.14M	1.32	-$74.62M	-$0.22	N/A

Summary

Sana Biotechnology beats MacroGenics on 9 of the 15 factors compared between the two stocks.

Get MacroGenics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MGNX vs. The Competition

Export

Metric	MacroGenics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$230.28M	$3.90B	$7.24B	$13.35B
Dividend Yield	N/A	3.65%	2.53%	17.39%
P/E Ratio	-16.43	13.44	274.58	26.17
Price / Sales	1.31	1,223.10	632.90	107.74
Price / Cash	N/A	126.56	79.41	53.24
Price / Book	4.11	16.25	10.87	6.30
Net Income	-$74.62M	-$22.68M	$3.50B	$381.95M
7 Day Performance	-6.35%	-3.87%	-1.13%	-0.80%
1 Month Performance	-17.84%	-11.96%	-6.30%	-5.26%
1 Year Performance	110.17%	14.39%	6.42%	0.89%

MacroGenics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MGNX MacroGenics	1.5177 of 5 stars	$3.55 -2.6%	$6.33 +78.7%	+106.8%	$225.94M	$175.14M	N/A	293	Positive News
ALMS Alumis	3.9268 of 5 stars	$7.29 +1.8%	$33.27 +356.4%	+68.2%	$943.55M	$24.05M	N/A	239	Positive News Analyst Forecast
ABUS Arbutus Biopharma	2.2977 of 5 stars	$4.69 -3.5%	$5.00 +6.6%	+3.2%	$929.14M	$14.08M	5.94	19	High Trading Volume
RIGL Rigel Pharmaceuticals	3.5147 of 5 stars	$48.89 -1.0%	$59.00 +20.7%	+59.6%	$904.47M	$294.28M	3.00	174
JBIO Jade Biosciences	2.0153 of 5 stars	$14.18 -1.2%	$51.75 +265.0%	+46.7%	$901.85M	N/A	N/A	55	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MGNX) was last updated on 10/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MacroGenics (MGNX) Competitors

MGNX vs. ALMS, ABUS, RIGL, JBIO, and SANA

How does MacroGenics compare to Alumis?

Summary

How does MacroGenics compare to Arbutus Biopharma?

Summary

How does MacroGenics compare to Rigel Pharmaceuticals?

Summary

How does MacroGenics compare to Jade Biosciences?

Summary

How does MacroGenics compare to Sana Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGNX vs. The Competition

MacroGenics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MacroGenics (MGNX) Competitors

MGNX vs. ALMS, ABUS, RIGL, JBIO, and SANA

How does MacroGenics compare to Alumis?

Do analysts prefer ALMS or MGNX?

Which has more risk and volatility, ALMS or MGNX?

Does the media prefer ALMS or MGNX?

Which has stronger valuation & earnings, ALMS or MGNX?

Do institutionals & insiders believe in ALMS or MGNX?

Is ALMS or MGNX more profitable?

Summary

How does MacroGenics compare to Arbutus Biopharma?

Which has stronger earnings and valuation, MGNX or ABUS?

Is MGNX or ABUS more profitable?

Do analysts rate MGNX or ABUS?

Do institutionals and insiders have more ownership in MGNX or ABUS?

Which has more volatility and risk, MGNX or ABUS?

Does the media favor MGNX or ABUS?

Summary

How does MacroGenics compare to Rigel Pharmaceuticals?

Which has more volatility & risk, MGNX or RIGL?

Is MGNX or RIGL more profitable?

Do analysts recommend MGNX or RIGL?

Which has stronger earnings & valuation, MGNX or RIGL?

Do insiders & institutionals hold more shares of MGNX or RIGL?

Does the media prefer MGNX or RIGL?

Summary

How does MacroGenics compare to Jade Biosciences?

Does the media favor MGNX or JBIO?

Which has better earnings & valuation, MGNX or JBIO?

Do insiders and institutionals have more ownership in MGNX or JBIO?

Do analysts recommend MGNX or JBIO?

Is MGNX or JBIO more profitable?

Which has more volatility and risk, MGNX or JBIO?

Summary

How does MacroGenics compare to Sana Biotechnology?

Is SANA or MGNX more profitable?

Do analysts recommend SANA or MGNX?

Do institutionals & insiders hold more shares of SANA or MGNX?

Which has more volatility & risk, SANA or MGNX?

Does the media favor SANA or MGNX?

Which has preferable earnings and valuation, SANA or MGNX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGNX vs. The Competition

MacroGenics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools